Stock of the Day

Genprex (GNPX)

$0.39

-$0.00 (-0.6%)

Market Cap: $3.36M

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.

Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Recent News

• Genprex announces advancement of diabetes program, strategic collaboration (markets.businessinsider.com)
• Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System (prnewswire.com)
• Genprex announces advancement of its diabetes gene therapy program (markets.businessinsider.com)
• Genprex Provides Update on Diabetes Gene Therapy Program (prnewswire.com)